Erika Hamilton/LinkedIn
Aug 20, 2025, 14:45
Erika Hamilton: Vepdegestrant Outperforms Fulvestrant in Advanced ER+HER2− Breast Cancer
Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared on LinkedIn about a recent paper by Patrick Neven et al. published on Nature:
“Great review of the vepdegestrant data presented at ASCO25 as well as the current status of the field post-1L CD4/6 inhibitor.”
Title: PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations
Authors: Patrick Neven and Sileny N. Han
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 17:43
Sep 9, 2025, 16:51
Sep 9, 2025, 15:59
Sep 9, 2025, 15:49
Sep 9, 2025, 15:46